Investor alert: law offices of howard g. smith announces investigation of immunitybio, inc. (ibrx) on behalf of investors

Bensalem, pa.--(business wire)--law offices of howard g. smith announces an investigation on behalf of immunitybio, inc. (“immunitybio” or the “company”) (nasdaq: ibrx) investors concerning the company's possible violations of federal securities laws. on may 11, 2023, before the market had opened, immunitybio announced that the fda had rejected the biologics license application for the company's immunotherapy drug, anktiva, due to “deficiencies relat[ing] to the fda's pre-license inspection of.
IBRX Ratings Summary
IBRX Quant Ranking